295 hasil
Menampilkan 1–20 · 0,60 detik · RSS
ESMO Gastrointestinal Oncology
Scopus
ISSN 2949-8198 · Elsevier · 295 artikel di indeks
-
Artikel Jurnal
The role of circulating tumor DNA (ctDNA) to detect minimal residual disease in locally advanced gastroesophageal carcinoma: the BUTTERFLY study
Background: Despite advances in perioperative and neoadjuvant strategies, patients with locally advanced gastroesophageal cancers remain at high risk of recurrence after curative intent treatment. No validated biomarkers are available to detect minimal residual disease (MRD) or to guide…
-
Artikel Jurnal
DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial
Background: Survival for patients with advanced oesophagogastric adenocarcinoma (OGA) is poor. Immune checkpoint inhibitor (ICI) monotherapy has limited efficacy in mismatch repair proficient (MMRp) OGA. Dickkopf-1 modulates Wnt/β-catenin signalling and promotes an immunosuppressive tumour…
-
Artikel Jurnal
Age-stratified mutation patterns in early-onset colorectal cancer reveal distinct molecular features and therapeutic implications☆
Background: Colorectal cancer (CRC) is increasingly diagnosed in younger adults, with evidence that early-onset cases (age
-
Artikel Jurnal
Adjuvant treatment of gastrointestinal stromal tumors (GIST)—state of the art, controversies, and future directions
Adjuvant treatment of gastrointestinal stromal tumors (GISTs) with imatinib has improved recurrence-free survival in patients at high risk of relapse after complete surgical resection. Nevertheless, its impact on overall survival (OS) remains limited, and optimal patient selection and treatment…
-
Artikel Jurnal
Tumor response to neoadjuvant treatment as a predictor of benefit for adjuvant treatment in esophago-gastric cancers: a systematic review and meta-analysis
Background: It is unclear which patients will benefit most from adjuvant chemotherapy for locally advanced esophago-gastric adenocarcinoma after systemic neoadjuvant treatment and resection. This study aims to systematically evaluate the efficacy of adjuvant chemotherapy in patients with resected…
-
Artikel Jurnal
A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma
Background: Drug-eluting bead transarterial chemoembolization (deb-TACE) is a standard for liver-limited, locally advanced hepatocellular carcinoma (HCC) and may enhance response to immune checkpoint inhibition through tumor immune microenvironment modulation. We evaluated nivolumab combined with…
-
Artikel Jurnal
Real-world efficacy, safety, and treatment continuity of fruquintinib in Japanese patients with colorectal cancer: a multicentre retrospective study
Background: Fruquintinib has recently been introduced as a later-line treatment option for unresectable or recurrent colorectal cancer (CRC) in Japan. However, real-world evidence from Japanese clinical practice remains limited; therefore, we evaluated the efficacy and safety of fruquintinib in…
-
Artikel Jurnal
Patterns of presentation and diagnostic delays in biliary tract cancers: a real-world European study
Background: Biliary tract cancers (BTCs) often present late due to nonspecific symptoms and a lack of effective population screening. We characterised diagnostic routes, symptom-to-diagnosis intervals, and their relationship with stage and outcomes across three European centres. Materials and…
-
Artikel Jurnal
A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial
Background: Definitive chemoradiotherapy is a standard treatment for unresectable locally advanced esophageal squamous cell carcinoma (LAESCC), but complete response rates remain 15%-25%, and median overall survival (OS) is 13-14 months. More effective strategies are needed. Trial design: The…
-
Artikel Jurnal
Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions
For patients with metastatic colorectal cancer (mCRC), defective mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status strongly predicts benefit from immune checkpoint inhibitors (ICIs). Based on the phase III KEYNOTE-177 and CheckMate 8HW trials, first-line treatment with ICIs…
-
Artikel Jurnal
Evaluating incidence and mortality trends of early-onset colorectal cancer and adenoma in Belgium
Background: Colorectal cancer (CRC) incidence is rising among young adults globally, yet European data remain inconclusive. This study evaluated age- and sex-specific trends in CRC incidence, adenoma detection, and mortality in Belgium, with a focus on individuals aged 20-49 years. Diagnostic…
-
Artikel Jurnal
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study
Background: A combination of gemcitabine, cisplatin and durvalumab (anti-programmed death-ligand 1) is the current standard-of-care first-line therapy for advanced biliary tract cancer (BTC). To date, there is only limited evidence regarding prognostic biomarkers. Studies in other tumour types…
-
Artikel Jurnal
Dose optimization of immune checkpoint inhibitors for gastrointestinal malignancies
Outcomes of patients with gastrointestinal (GI) malignancies have improved substantially since the introduction of immunotherapy, with immune checkpoint inhibitors (ICIs) approved for specific subsets. Two biomarkers (mismatch repair/microsatellite instability status and programmed death-ligand 1…
-
Artikel Jurnal
Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors
Background: Everolimus is effective in advanced neuroendocrine tumors (NETs) but is associated with substantial toxicity and high long-term costs. Real-world data suggest that lower doses (≤6 mg/day) achieve comparable efficacy with reduced toxicity compared with standard-dose therapy. This study…
-
Artikel Jurnal
Additional benefit of standardized computed tomography-based lymph node assessment utilizing Node-RADS in esophageal adenocarcinoma
Background: Accurate lymph node staging is crucial for treatment stratification in esophageal adenocarcinoma. While endoscopic ultrasound (EUS) is standard for locoregional staging, computed tomography (CT) remains essential for detecting distant metastasis. This study aims to evaluate the Node…
-
Artikel Jurnal
Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial
Background: Immune checkpoint inhibitors (ICIs) have shown limited efficacy in patients with microsatellite-stable/DNA mismatch repair-proficient (MSS/pMMR) metastatic colorectal cancer (CRC). Based on data suggesting antitumor synergy between ICIs and MEK inhibitors, the phase II CheckMate 142…
-
Artikel Jurnal
ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy—phase II investigator-initiated trial (NCCH2412/MK015)
Background: Small bowel adenocarcinoma (SBA) is a rare cancer with limited treatment strategies beyond first-line platinum-based combination therapy and no established second-line standard. Our recent retrospective study showed that Nectin-4 is frequently highly expressed in SBA and is associated…